Slide 1: BONESUPPORT Q2 (2024) Report
BONESUPPORT Q2 (2024) Report July 11, 2024 Emil Billbäck, CEO Håkan Johansson, CFO
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: BONESUPPORT – Second quarter report 2024
BONESUPPORT – Second quarter report 2024 Q2 2024: • Net sales SEK 220 m, growth: +57% versus Q2 2023, (+55% in constant exchange rates, CER) • US CERAMENT G sales of 108 mSEK • Operating result (before accounting effects of incentive programs): SEK 36 m (SEK 14 m) • Reported EBIT: SEK 29 m (SEK 6 m)
Slide 4: Strong launch momentum for CERAMENT G in the US
Strong launch momentum for CERAMENT G in the US • CERAMENT G in the US surpassing 100 mSEK in the quarter • Total antibiotic eluting CERAMENT grew with 82% versus Q2 2023 CBVF= CERAMENT Bone Void Filler CG = CERAMENT G (Gentamicin) CV = CERAMENT V (Vancomycin) 4 NA CBVF also contains sales from appl
Slide 5: North America: Strong market penetration and surgeon preference
North America: Strong market penetration and surgeon preference Q2 2024 • Sales of SEK 173 m, growth of 67% over Q2 2023 (growth of 66% in constant exchange rate, CER) • Sales in Q2 2024 represented a reported sequential growth of 22% over Q1 2024 • CERAMENT BVF grew with 13% in Q2 2024 over Q2 2023
Slide 6: EUROW Market share gains fuels sales performance
EUROW Market share gains fuels sales performance Q2 2024 • Sales of SEK 47 m, growth of 28% vs Q2 2023, (growth of 26% in constant exchange rates, CER) • Positive market dynamics – continued catch up of surgical back-log • Strong sales development following market share gains Highlights • Clinical d
Slide 7: Financial Report
BONESUPPORT Q2 (2024) Report Financial Report
Slide 8: Q2 2024 net sales SEK 219,8 m
Q2 2024 net sales SEK 219,8 m SEK m • NA: 67 percent reported growth. 66 percent growth in CER • EUROW: 28 percent reported growth. 26 percent growth CER • Low impact from currency movements 9
Slide 9: Gross Margin and Net Sales by Segment
North America +67% EUROW +28% (+66% CER) (+26% CER) Net sales Net sales Q2-24 Q2-24 North America 2024 2023 EUROW 2024 2023 SEK m Q2-24 Q1-24 Q4-23 Q3-23 Q2-23 SEK m Q2-24 Q1-24 Q4-23 Q3-23 Q2-23 Net Sales 173,0 141,5 131,6 121,0 103,9 Net Sales 46,8 43,0 41,1 37,2 36,5 Gross profit 165,7 134,8 125,
Slide 10: Investments in commercial and innovation impacting the quarter
Investments in commercial and innovation impacting the quarter Key Figures 2024 2023 2022 SEK m Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Selling expenses 67,6 59,7 59,6 53,5 55,0 49,0 46,8 38,8 Sales Commissions and fees 62,2 48,2 44,4 42,7 37,2 29,9 28,1 21,1 Research and Development expenses 20,3 14,1 17,6 12,5 14
Slide 11: Solid profit performance despite commercial and R&D initiatives
Solid profit performance despite commercial and R&D initiatives Key Figures 2024 2023 2022 SEK m Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Net Sales 219,8 184,4 172,7 158,2 140,4 119,7 103,2 84,6 Gross Margin (%) 92,3 92,6 91,8 92,1 91,3 90,5 91,5 90,8 Operating profit 28,7 32,3 -8,0 14,9 6,0 0,8 -19,3 -13,9 Adj. Ope
Slide 12: BONESUPPORT Q2 (2024) Report: Raised guidance
BONESUPPORT Q2 (2024) Report • 57% sales growth • SEK 36 m EBIT (before incentive cost) • Strong performance for CERAMENT G USA • Spine pre-clinical studies started Raised guidance: Sales in 2024 to grow more than 50% vs 2023 (in constant exchange rates) 13